Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$30.28 -0.6%	$30.15	$23.12 ▼ $36.45	$4.99B	0.44	1.74 million shs	1.48 million shs
FOLD Amicus Therapeutics	$6.09 -3.3%	$6.07	$5.51 ▼ $12.65	$1.88B	0.51	3.23 million shs	2.56 million shs
INVA Innoviva	$18.77 -1.5%	$19.79	$16.67 ▼ $22.00	$1.18B	0.37	705,522 shs	764,766 shs
LGND Ligand Pharmaceuticals	$121.70 -2.6%	$109.40	$90.29 ▼ $129.90	$2.35B	0.84	116,645 shs	106,482 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+5.32%	-1.62%	+12.15%	+31.59%
FOLD Amicus Therapeutics	0.00%	-1.06%	-1.30%	-6.02%	-41.05%
INVA Innoviva	0.00%	-2.24%	-12.29%	+7.13%	+11.86%
LGND Ligand Pharmaceuticals	0.00%	+6.40%	+6.33%	+16.72%	+26.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.7992 of 5 stars	4.4	1.0	4.2	2.9	2.5	1.9
FOLD Amicus Therapeutics	4.1448 of 5 stars	3.4	1.0	4.3	3.3	0.0	1.9
INVA Innoviva	4.2067 of 5 stars	3.5	0.0	4.2	2.8	1.7	1.9
LGND Ligand Pharmaceuticals	4.104 of 5 stars	2.5	1.0	4.4	2.1	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.00	32.10% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	166.37% Upside
INVA Innoviva	3.00	Buy	$40.50	115.77% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	20.93% Upside

Current Analyst Ratings Breakdown

Latest INVA, ALKS, LGND, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	INVA Innoviva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00
5/13/2025	ALKS Alkermes	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/2/2025	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/2/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$39.00 ➝ $40.00
5/2/2025	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $41.00
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
5/2/2025	FOLD Amicus Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $9.00
4/28/2025	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.21	$2.65 per share	11.42	$9.05 per share	3.35
FOLD Amicus Therapeutics	$528.29M	3.55	N/A	N/A	$0.65 per share	9.37
INVA Innoviva	$358.71M	3.29	$3.43 per share	5.48	$11.03 per share	1.70
LGND Ligand Pharmaceuticals	$167.13M	14.05	$1.61 per share	75.74	$43.95 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	14.49	22.10	1.88	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	14.16	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
INVA Innoviva	$23.39M	-$1.01	N/A	12.11	N/A	-16.15%	15.77%	8.41%	7/29/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	32.80	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)

Latest INVA, ALKS, LGND, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
7/29/2025	Q2 2025	INVA Innoviva	$0.43	N/A	N/A	N/A	$87.10 million	N/A
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
FOLD Amicus Therapeutics	2.02	3.34	2.47
INVA Innoviva	0.40	2.48	2.30
LGND Ligand Pharmaceuticals	N/A	5.27	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
FOLD Amicus Therapeutics	N/A
INVA Innoviva	99.12%
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
FOLD Amicus Therapeutics	2.20%
INVA Innoviva	2.25%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable

INVA, ALKS, LGND, and FOLD Headlines

Recent News About These Companies

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ... - Nasdaq

July 12 at 1:54 PM | nasdaq.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 934 Shares

July 12 at 6:25 AM | insidertrades.com

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)

July 11 at 8:14 PM | gurufocus.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock

July 11 at 7:52 PM | marketbeat.com

Ligand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | Benzinga

July 11 at 5:49 PM | benzinga.com

Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI

July 10 at 11:40 PM | finanznachrichten.de

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

July 10 at 8:00 AM | globenewswire.com

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What Happened

July 9, 2025 | marketbeat.com

Brokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $146.14

July 8, 2025 | americanbankingnews.com

Calamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 6, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (LGND) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from Analysts

July 5, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 4, 2025 | marketbeat.com

Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July

July 2, 2025 | finanznachrichten.de

Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals

July 2, 2025 | quiverquant.comQ

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

July 2, 2025 | globenewswire.com

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

July 2, 2025 | globenewswire.com

Lisanti Capital Growth LLC Acquires 13,565 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 29, 2025 | marketbeat.com

LGND Ligand Pharmaceuticals Incorporated - Seeking Alpha

June 26, 2025 | seekingalpha.com

Andrew Reardon Sells 500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock

June 26, 2025 | insidertrades.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,040.00 in Stock

June 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
By Gabriel Osorio-Mazilli | June 16, 2025
View China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
Tariff Talks Advance, What Taiwan Semiconductor Can Deliver
By Gabriel Osorio-Mazilli | June 16, 2025
View Tariff Talks Advance, What Taiwan Semiconductor Can Deliver

INVA, ALKS, LGND, and FOLD Company Descriptions

Alkermes NASDAQ:ALKS

$30.28 -0.18 (-0.59%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$30.54 +0.26 (+0.86%)

As of 07/11/2025 06:00 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Amicus Therapeutics NASDAQ:FOLD

$6.09 -0.21 (-3.33%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$6.24 +0.15 (+2.45%)

As of 07/11/2025 05:41 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Innoviva NASDAQ:INVA

$18.77 -0.29 (-1.52%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$17.86 -0.91 (-4.84%)

As of 07/11/2025 07:45 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Ligand Pharmaceuticals NASDAQ:LGND

$121.70 -3.28 (-2.62%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$121.72 +0.02 (+0.02%)

As of 07/11/2025 07:06 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time